California Public Employees Retirement System Buys 82,032 Shares of Anika Therapeutics Inc (NASDAQ:ANIK)

California Public Employees Retirement System grew its stake in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 386.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 103,279 shares of the biotechnology company’s stock after acquiring an additional 82,032 shares during the quarter. California Public Employees Retirement System owned about 0.72% of Anika Therapeutics worth $5,355,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of ANIK. Millennium Management LLC boosted its position in shares of Anika Therapeutics by 379.9% during the third quarter. Millennium Management LLC now owns 191,961 shares of the biotechnology company’s stock valued at $10,536,000 after buying an additional 151,961 shares during the last quarter. Nuveen Asset Management LLC purchased a new stake in shares of Anika Therapeutics during the second quarter valued at $2,288,000. SG Americas Securities LLC boosted its position in shares of Anika Therapeutics by 719.7% during the third quarter. SG Americas Securities LLC now owns 47,176 shares of the biotechnology company’s stock valued at $2,589,000 after buying an additional 41,421 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Anika Therapeutics by 4.1% during the third quarter. Rhumbline Advisers now owns 44,883 shares of the biotechnology company’s stock valued at $2,464,000 after buying an additional 1,765 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Anika Therapeutics by 10.6% during the third quarter. Barclays PLC now owns 35,165 shares of the biotechnology company’s stock valued at $1,930,000 after buying an additional 3,366 shares during the last quarter. Hedge funds and other institutional investors own 96.60% of the company’s stock.

Several equities research analysts recently commented on ANIK shares. BidaskClub cut Anika Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 13th. First Analysis raised Anika Therapeutics from an “outperform” rating to a “strong-buy” rating and set a $65.00 price objective on the stock in a research report on Friday, January 10th. ValuEngine cut Anika Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 4th. TheStreet cut Anika Therapeutics from a “b” rating to a “c+” rating in a research report on Friday, January 31st. Finally, Zacks Investment Research raised Anika Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 6th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Anika Therapeutics has a consensus rating of “Hold” and an average target price of $54.80.

Shares of NASDAQ:ANIK opened at $41.48 on Friday. The stock has a market capitalization of $592.46 million, a price-to-earnings ratio of 19.22, a PEG ratio of 2.59 and a beta of 0.97. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.74 and a current ratio of 19.99. The stock’s 50-day simple moving average is $46.50 and its two-hundred day simple moving average is $54.54. Anika Therapeutics Inc has a 52-week low of $29.01 and a 52-week high of $75.71.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

Read More: Dividend Reinvestment Plan (DRIP)

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.